c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.

Cat. No.	Product name	CAS No.	Purity
T9052	XL092	2367004-54-2	99.51%
T9052	XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
T2185	L-Ascorbic acid 2-phosphate trisodium	66170-10-3	99.5%
T2185	L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is used in biocatalytic dephosphorylation for electric power generation and electrochemical det...
T10585	Bozitinib	1440964-89-5	99.48%
T10585	Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional AT...
T4426	CEP-40783	1437321-24-8	99.45%
T4426	CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
T5478	SRI 31215 TFA	1832686-44-8	99.36%
T5478	SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF ...
T6128	PHA-665752	477575-56-7	99.35%
T6128	PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
T1661	Crizotinib	877399-52-5	99.35%
T1661	Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
T22324	Ensartinib hydrochloride	2137030-98-7	99.29%
T22324	Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known cr...
T6260	AMG-208	1002304-34-8	99.27%
T6260	AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
T8416	Capmatinib xHCl	1029714-89-3	99.24%
T8416	Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 =...
T2699	BMS 777607	1025720-94-8	99.22%
T2699	BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of ...
T6351	MGCD-265 analog	875337-44-3	99.21%
T6351	MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 n...
T13108	Pamufetinib	1190836-34-0	99.15%
T13108	Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rME...
T1797	Cabozantinib S-malate	1140909-48-3	98.87%
T1797	Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with pot...
T2349	BMS-754807	1001350-96-4	98.86%
T2349	Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine ...
T8409	SYN1143	913376-84-8	98.86%
T8409	SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50...
T15617	JNJ-38877618	943540-74-7	98.84%
T15617	JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
T3550	X-376	1365267-27-1	98.72%
T3550	X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
T2680	NVP-BVU972	1185763-69-2	98.61%
T2680	NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
T2676	PF-04217903	956905-27-4	98.55%
T2676	MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.